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A relevant fraction of castration-resistant prostate cancers (CRPC) evolve into fatal
neuroendocrine (NEPC) tumors in resistance to androgen deprivation and/or inhibitors
of androgen receptor pathway. Therefore, effective drugs against both CRPC and
NEPC are needed. We have previously described a dual role of mast cells (MCs) in
prostate cancer, being capable to promote adenocarcinoma but also to restrain NEPC.
This finding suggests that a molecule targeting both MCs and NEPC cells could be
effective against prostate cancer. Using an in silico drug repurposing approach, here
we identify the antiepileptic drug levetiracetam as a potential candidate for this purpose.
We found that the protein target of levetiracetam, SV2A, is highly expressed by both
NEPC cells and MCs infiltrating prostate adenocarcinoma, while it is low or negligible
in adenocarcinoma cells. In vitro, levetiracetam inhibited the proliferation of NEPC cells
and the degranulation of MCs. In mice bearing subcutaneous tumors levetiracetam was
partially active on both NEPC and adenocarcinoma, the latter effect due to the inhibition of
MMP9 release by MCs. Notably, in TRansgenic Adenocarcinoma of the Mouse Prostate
(TRAMP) mice subjected to surgical castration to mimic androgen deprivation therapy,
levetiracetam reduced onset and frequency of both high grade prostatic intraepithelial
neoplasia, adenocarcinoma and NEPC, thus increasing the number of cured mice
showing only signs of tumor regression. Our results demonstrate that levetiracetam
can directly restrain NEPC development after androgen deprivation, and that it can also
block adenocarcinoma progression through the inhibition of some MCs functions. These
findings open the possibility of further testing levetiracetam for the therapy of prostate
cancer or of MC-mediated diseases.
Keywords: prostate cancer, neuroendocrine differentiation, mast cells, drug repurposing, tumor
microenvironment, mouse models
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INTRODUCTION
Prostate cancer is the most commonly diagnosed malignancy
worldwide and is the second leading cause of cancer death
among men (1). Androgen deprivation therapy (ADT) is the
treatment of choice for advanced/metastatic adenocarcinoma,
but its efficacy is limited, as tumors become castration resistant
(CRPC). Patients with CRPC may be treated with agents
inhibiting the androgen receptor pathway (ARPI), such as the
AR antagonist enzalutamide. These treatments can delay tumor
progression despite the failure of ADT, but resistance eventually
occurs. Mechanisms of resistance rely on cellular plasticity and
neuroendocrine differentiation of adenocarcinoma (CRPC-NE
or treatment-related NEPC), emerging in a relevant fraction of
patients (2–5). Treatment-related NEPC is characterized by few
genomic alterations, including N-Myc expression, Rb loss and
p53 mutations, and by de-regulation of several epigenetic and
transcription factors (2, 6). This aggressive variant of prostate
cancer can very rarely occur also in untreated patients and in
this case it is called de-novo NEPC (7). Interestingly, despite
treatment-related NEPC and de-novo NEPC present different
genomic alterations they share a common transcriptional profile
(8). No definitive therapeutic options are available for NEPC,
and further study of the molecular mechanisms that stimulate its
emergence is necessary to identify novel targets.
Whether and how the tumor microenvironment can
contribute to NEPC outgrowth is still poorly investigated. We
recently demonstrated that mast cells (MCs) can favor the
growth of prostate adenocarcinoma, providing MMP9 at initial
stages (9) and inhibiting the anti-tumor immune response (10).
On the contrary, we surprisingly found that they are also able
to restrain the occurrence of NEPC through a yet undefined
mechanism (9, 11).
This dual role of MCs might be considered when searching
novel therapeutic options for prostate cancer. Indeed, the
mere targeting of MCs function could be effective against
adenocarcinoma but detrimental if not combined with drugs
specific for NEPC. Here, instead, we investigate an alternative
approach that considers a single drug directed to a target
expressed on both MCs and NEPC cells.
Drug repurposing, or repositioning, is a strategy based on
the identification of new therapeutic applications of existing
drugs (12). This approach has several advantages compared
to conventional drug discovery, being less time and money
consuming. Indeed, as toxicity and safety studies have already
been performed, this facilitates and accelerates the use of
repurposed drugs in clinical trials (13). Approaches for drug
repositioning, with successful examples also in prostate cancer,
can be divided in knowledge-based, activity-based and in-silico
based (14). The latter is herein applied.
MATERIALS AND METHODS
Mice and Treatments
TRAMP mice on C57BL6/J background (C57BL/6-tgN
(TRAMP)8247Ng; RRID: MGI:3795485) were kindly provided
by Dr. Vincenzo Bronte (Verona University Hospital, Italy),
under agreement with Dr. NormanMichael Greenberg (formerly
at Fred Hutchinson Cancer Research Center, Seattle, WA,
USA), maintained and screened according to (15). Surgical
castration was performed in 20 weeks old TRAMP mice, under
anesthesia with ketamine (100 mg/Kg; Imalgene, Boeringher
Ingheilm) and xilazine (5 mg/Kg; Rompun, Bayer). Carprofene
(5 mg/Kg; Norocarp, Norbrook) was given before the operation
and after recovery post anesthesia. Levetiracetam (Hikma
Farmaceutica, 100 mg/ml concentrate for solution for infusion)
was administered in drinking water, in a dose corresponding to
60 mg/Kg day, as given in patiens (16, 17), starting 1-week post
castration. Cromolyn (10 mg/kg; Sigma Aldrich, Milan, Italy)
was diluted in saline solution and injected intraperitoneum (i.p.)
for 5 days/week. All transgenic mice were sacrificed at 30 weeks
of age. For subcutaneous tumor challenge, T1525, T23, or ST4787
cells (respectively, 2 × 106, 2× 106, or 1 × 106 cell/mouse) were
injected in the right flank of C57BL/6 male mice. Mice were
monitored twice a week and sacrificed when tumor diameters
reached 10mm × 10mm. Levetiracetam and cromolyn were
administered as described above, starting from day 4 post tumor
challenge. Animal housing and experimentation were approved
by the Italian Ministry of Health and performed in accordance
to Italian law (D.lgs 26/2014-approval number 515/2016-PR).
Cell Lines and in vitro Experiments
T1525 and T23 prostate adenocarcinoma cell lines were isolated
from TRAMP mice as described (9). ST4787 were isolated from
a NEPC spontaneously arisen in a TRAMP mouse genetically
deficient for the protein SPARC. One prostate lobe was fixed in
formalin for histopathological evaluation, whereas the remaining
tissue was digested with 1 mg/ml collagenase I (Gibco) for 2h
at 37◦C. Collected cells were plated to establish the ST4787 cell
line. ST4787 cells and tumors generated by their subcutaneous
injection in C57BL/6 syngeneic mice maintain the NEPC
phenotype, as shown in Supplementary Figure 1. All cells were
cultured in DMEM (Gibco) supplemented with 10% of fetal
bovine serum (FBS; Gibco), 200 U/mL penicillin (Cambrex),
150 U/mL streptomycin, 10 mmol/L Hepes, 10 mmol/L sodium
pyruvate (Gibco) and 2 mmol/L L-glutamine. All cell lines
were routinely tested for Mycoplasma using the MicoAlert
Mycoplasma Detection Kit (Lonza, cat no. LT07-118). No other
authentication method was performed.
Bone Marrow-Derived MCs (BMMCs)
Differentiation
Bone marrow–derived MCs (BMMCs) were obtained by in vitro
differentiation of bone marrow cells taken from mouse femurs
and tibias, in RPMI (Gibco) with 10% FBS, 200 U/mL penicillin
(Cambrex), 150 U/mL streptomycin, 10 mmol/L Hepes, 10
mmol/L sodium pyruvate (Gibco), and 2 mmol/L L-glutamine
and 5 mmol/L beta-mercaptoethanol (Gibco), in the presence
of IL-3 (20 ng/ml; Peprotech, cat. no. AF-213-13). After 5
weeks of culture, BMMCs were monitored for FceRI and c-Kit
expression by flow cytometry and used if purity was more than
95%. Antibodies used were FITC-conjugated hamster anti-mouse
FcεRI monoclonal antibody (Biolegend, clone MAR-1, cat. no.
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134305, RRID: AB_1626102) and PE/Cy7-conjugated rat anti-
mouse CD117 (c-kit) monoclonal antibody (Biolegend, clone
2B8, cat. no. 105813; RRID: AB_313222.
BMMCs Activation, Degranulation Assays,
Leukotrienes, and Cytokine Secretion
For functional in vitro assays, 2 × 106/ml BMMCs were either
left untreated (Ctr -) or stimulated for 24 h with 1µg/ml LPS or
1µg/ml ionomycin (Iono, Sigma). For activation with IgE and
specific antigen (IgE/Ag), 1 × 106/ml BMMCs were previously
sensitized in complete RPMI medium for 3 h with 1µg/ml
of dinitrophenol (DNP)-specific IgE, washed twice, and then
challenged 1 h with 100 ng/ml DNP (Sigma-Aldrich).
BMMCs degranulation response was determined as the
percentage of beta-hexosaminidase released. 0.5 × 106 BMMCs
were challenged in Tyrode’s buffer (130mM NaCl, 10mM
HEPES buffer [pH 7.4], 5.6mM glucose, 5mM KCl, 1.4mM
CaCl2, 1mM MgCl2 and 0.1% bovine serum albumin) with the
indicated stimuli. The enzymatic activity of the released beta-
hexosaminidase was assessed by the cleavage of its synthetic
substrate (p-nitrophenyl N-acetyl-glucosamide, Sigma Aldrich)
in p-nitrophenol and measuring the p-nitrophenol absorbance
at 405 nm with a plate spectrophotometer. Results are expressed
as the percentage of beta-hexosaminidase released over beta-
hexosaminidase retained in the cytoplasm.
Leukotrienes C4, D4, and E4 were measured using a specific
detection kit (Leukotriene C4/D4/E4, BiotrakTM EIA System,
cat. no. RPN224, Cytivia formerly GE Healthcare Life Sciences)
according to manufacturer’s instructions.
Cytokine release was assessed by ELISA on cells supernatants,
with specific kits (all from Invitrogen by Thermo Fisher
Scientific; RRID:SCR_008452) for IL-6 (cat. no. 88-7064), TNF-
α (cat. no. 88-7324), and MMP9 (cat. no. EMMMP9) following
the manufacturer’s instructions.
In vitro Cell Proliferation
For proliferation experiments, cells were plated in 96-well-
plates (5,000 cells/well) in presence of different concentrations
of levetiracetam (0, 1, 10, 25, or 50 mmol/L). After 48 h,
cell proliferation was assessed using the XTT cell-viability
kit (Applichem, Germany, cat. no. A8088) according to the
manufacturer’s protocol.
Cytospin
Tumor cells or MCs were suspended at 105 cells/100ml. Glass
slides were mounted with paper pads and cuvettes with a
metal holder, loaded with 100ml of cell suspension and then
centrifuged 2min at 2,000 rpm with a cytocentrifuge. After
detaching of cuvettes and filters, slides were dried overnight and
then fixed for 20min with PBS containing 2% paraformaldehyde
(PFA). For immunofluorescence, after permeabilization for
10min with PBS containing 0.5% Saponin (Sigma) and blocking
with PBS containing 5% bovine serum albumin (BSA; Sigma)
we followed the protocol described for paraffin-embedded
tumor sections.
Classification of Tumor Lesions in
Castrated Mice
Murine urogenital apparata were fixed in formalin and embedded
in paraffin. Sections (5µM) were de-paraffined and re-hydrated,
stained with H&E (BioOptica) and evaluated by a pathologist.
In serial sections, immunofluorescence for luminal (CK8) and
neuroendocrine (SYP) markers was performed. Please refer to
the next section for specific details on immunofluorescence
protocol. Murine prostate lesions were scored according
to histopathological and immunophenotypical analyses as
follows. Lesions defined as high-grade prostatic intraepithelial
neoplasia (HGPIN) or initial adenocarcinoma (ADENO) were
characterized by CK8 positive atypical cells forming distorted/ill-
defined glands within the stroma. NEPC was composed of
sheets and nests of medium-sized to large cells with high
nuclear to cytoplasmic ratio and/or anaplastic morphology.
Cells were immunoreactive for SYP and either negative (in
case of pure small-cell NE carcinoma) or positive for CK8 [in
case of tumors with mixed adenocarcinoma and NE features,
ref. (5)]. Regression (REG) was marked by a variable degree
of glandular distortion characterized by dilated lumina with
flattened or focally hyperplastic epithelia in the absence of overt
nuclear atypia.
Immunohistochemistry and
Immunofluorescence
Tumor samples were fixed in formalin and embedded in paraffin.
Sections (5µM) were de-paraffined and re-hydrated. Unless
alternatively specified, antigen retrieval was performed utilizing
the Novocastra Epitope Retrival Solution pH9 (Novocastra, Leica
Biosystems), at 98◦C for 30min. For immunohistochemistry,
sections were then brought to room temperature and washed
with PBS. After neutralization of the endogenous peroxidase
with 3% H2O2 and Fc blocking by a specific protein block,
staining was revealed using a polymer detection kit (Novocastra,
Leica Biosystems) or HRP-conjugated donkey anti-rabbit
IgG specific secondary antibody (GE Healthcare, cat. no.
RPN1004V, RRID: AB_1062582, dilution 1:300) and AEC
(3-Amino-9-ethylcarbazole) as chromogenic substrate, followed
by counterstaining with Harris hematoxylin (Novocastra, Leica
Biosystems). Primary antibodies were: rabbit anti mouse/human
SV2A polyclonal antibody (Abcam cat. no. 32942; RRID:
AB_778192; dilution 1:200) and rabbit anti mouse/human
MMP9 polyclonal antibody (Abcam cat. no. ab38898; RRID:
AB_776512; dilution 1:500). Slides were acquired with a Leica
DM4 B microscope equipped with a Leica DFC450C digital
camera, utilizing the LAS 4.8 software (Leica Biosystems).
Staining intensity was quantified using the Image J software
(RRID: SCR_003070). For immunofluorescence the following
antibodies were used: alexa fluor 488-conjugated rabbit anti
mouse/human CK8 monoclonal antibody (Abcam; clone
EP1628Y, cat. no. ab192467, RRID: AB_2864346, dilution
1:200), alexa fluor 555-conjugated rabbit anti mouse SYP
monoclonal antibody (Abcam; clone YE269, cat. no. ab206870,
RRID: AB_2864347, dilution 1:100), unconjugated rabbit anti
mouse/human SV2A polyclonal antibody (Abcam cat. no.
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32942; RRID: AB_778192; dilution 1:200), unconjugated rabbit
anti-mouse/human mast-cell tryptase monoclonal antibody
(Abcam; cat. no. ab134932, RRID: AB_2811029; dilution 1:100),
unconjugated rabbit anti-mouse/human MMP9 polyclonal
antibody (Abcam cat. no. ab38898; RRID: AB_776512; dilution
1:500). Secondary antibodies were: alexa fluor 555 conjugated
donkey anti-rabbit IgG (H+L) polyclonal antibody (Invitrogen;
cat. no. A-31572, RRID: AB_162543; dilution 1:500); alexa
fluor 488 conjugated goat anti-rabbit IgG (H+L) polyclonal
antibody (Invitrogen; cat. no. A-11034, RRID: AB_2576217;
dilution 1:500).
For double CK8/SYP staining after antigen retrieval sections
were blocked with PBS-Tween (0.1%) containing 5% of BSA.
Primary conjugated antibodies were simultaneously incubated
overnight at 4◦C. For double MMP9/tryptase staining, after
antigen retrieval sections were blocked with PBS-Tween (0.1%)
containing 5% of BSA. Primary anti-tryptase antibody was
incubated 1 h at room temperature; after washing with PBS,
secondary antibody was added for 30min at room temperature.
After extensively washing with PBS, we repeated the procedure
with anti-MMP9 primary antibody 1 h at room temperature and
secondary antibody 30min at room temperature.
For double SV2A/tryptase staining, the Opal Multiplex IHC
kit (PerkinElmer) was developed. Antigen retrieval in pH9
buffer was brought to a boil at 100% power, followed by 20%
power for 15 minutes using microwave. Sections were treated
with blocking buffer for 10min at room temperature before
primary antibody incubation. Slides were then incubated with
Polymeric horseradish peroxidase-conjugated (HRP) secondary
antibody for 10 minutes and the signal was visualized using
Opal 520 fluorophore-conjugated tyramide signal amplification
(TSA) at 1:50 dilution. The HRP catalyze covalent deposition
of fluorophores around the marker of interest. The slides
were again processed with the microwave treatment to strip
primary/secondary antibody complex and allow the next antigen-
antibody staining. Another round of staining was performed
with the second primary antibody incubation, followed by HRP-
conjugated secondary antibody and Opal 620 fluorophore-TSA
conjugated at 1:50 dilution.
Staining with DAPI (ThermoFisher Scientific) was performed
for 10min at room temperature. Slides were mounted with
ProLong Diamond AntifadeMountant (ThermoFisher Scientific;
RRID:SCR_008452), and acquired with a Leica DM4 B
microscope equipped with a Leica DFC450C digital camera,
utilizing the LAS X software (Leica Biosystems). Images were
mounted using the Image J software (RRID: SCR_003070).
Real-Time PCR
Total RNA (including both long and short RNAs) from
cells was extracted using the Quick RNA micro prep kit
(Zymo Research). cDNA was obtained using the MultiScribeTM-
Reverse Transcriptase kit (Applied Biosysyems). RT-PCR was
performed in a total volume of 200 µL using the Taqman R©
Fast Universal PCR Master Mix (Applied Biosystems), 20
ng of cDNA and specific probes for Ar (Mm00442688_m1),
Syp (Mm00436850_m1), Ezh2 (Mm_00468464_m1), and Gapdh
(Mm99999915_g1), all from Applied Biosystems. Values were
normalized to internal control (Gapdh) and analyzed using the
1CT method.
Western Blot
5 × 106 BMMCs and 2 × 106 T1525, T23, and ST4787 cells
were lysed in 50 µl NP-40 buffer (25mM Tris-HCl [pH 7.4],
150mM NaCl, 1mM EDTA, 1% NP-40 and 5% glycerol, 1mM
Na3VO4, 50mM NaF; Sigma Aldrich), containing protease
inhibitor cocktail (Sigma, cat no.P8340) for 10 minutes on ice.
Lysates were then centrifuged at 12,000 × g, 4◦C for 10min and
supernatants were collected and stored at −80◦C. For western
blot analysis, lysates were diluted with 4× Laemmli buffer and
denatured 7min at 95◦C, separated on SDS 10% polyacrylamide
gels and blotted on a nitrocellulose membrane (Amersham) at
300V, 250mA, 4◦C for 3 h. Membranes were blocked in TBS-
T (20mM Tris-base [pH 7.6], 150mM NaCl, 0.05% Tween-
20) containing 5% BSA for 1 h at room temperature. Primary
antibodies were diluted 1:500 in TBS-T containing 5% BSA and
membranes probed overnight at 4◦C with gentle agitation. HRP-
conjugated secondary antibodies were incubated for 1 h at room
temperature with gentle agitation. Signals were detected using
Super SignalWest Femto (Thermo Scientific cat no. 34096; RRID:
SCR_008452) and acquired with a ChemiDoc imaging system
(BioRad; RRID: SCR_019037). Quantification was performed
with the Image J software (RRID: SCR_003070).
Primary antibodies were: rabbit anti-mouse/human SV2A
polyclonal antibody (Abcam; cat. No. 32942 RRID: AB_778192,
dilution 1:500) and mouse anti-mouse/human actin monoclonal
antibody (Becton Dickinson; clone C4, cat. no. 612656, RRID:
AB_2289199; dilution 1:1,000). Secondary antibodies HRP
conjugated were: goat anti-mouse IgG (Thermo Fisher Scientific;
RRID:SCR_008452; cat. no. 1858413, RRID:AB_1185566,
dilution 1:2,500), and goat anti-rabbit IgG (Thermo Fisher
Scientific RRID:SCR_008452; cat. no. 1858415, RRID:
AB_228341, dilution 1:2,500).
Analyses of Mouse and Human NEPC Data
Sets
Raw data derived from gene expression profiling of
adenocarcinoma and NEPC spontaneously occurring in
TRAMP mice (18), of NEPC occurring in TRAMP mice
following pharmacologic inhibition of MCs with cromolyn
(9) and of TRAMP-derived prostate-cancer stem like cells
with NEPC or adenocarcinoma features (19) were analyzed
with the limma package available within Bioconductor (RRID:
SCR_010943) (20). Class comparison was performed to retrieve
NEPC-associated transcripts with log2 fold change >1 and
with adjusted p < 0.05 were selected. Mouse gene symbols
were converted into orthologous human gene symbols with the
biomaRt package (21) and then intersected with up-regulated
genes in human metastatic NEPC vs. CRPC (2). MetaCore
version 19.4 (Clarivate Analytics, Philadelphia, PA, USA; RRID:
SCR_008125) was used for target identification.
Statistical Analyses
Statistical analysis was performed with the GraphPad
Prism software (GraphPad Software, La Jolla, CA, USA;
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FIGURE 1 | SV2A transcript and protein is overexpressed in human NEPC. (A)
We looked for transcripts up-regulated in NEPC analyzing gene expression
(Continued)
FIGURE 1 | profiles that we previously obtained in TRAMP mice with
adenocarcinoma or NEPC [“Mouse NEPC,” ref (9, 18)] and public available
profiles of TRAMP-derived prostate cancer stem-like cells with NEPC or
adenocarcinoma features [“NEPC cell lines,” ref (19)] and of human NEPC and
CRPC patients [“human NEPC,” ref (2)]. Venn diagrams show the intersection
of up-regulated genes in NEPC in the three data sets. (B) List of the 20 genes
commonly up- regulated in mouse NEPC, NEPC cell lines and human NEPC,
with indication of specific targeting drugs, when available, identified with the
Metacore software. (C) Immunohistochemistry for SV2A (brown staining) in
human prostate adenocarcinoma (upper panels; black arrows indicate positive
tumor glands, red arrows indicate positive stroma cells) or NEPC (lower
panels). Scale bars indicate magnifications.
RRID:SCR_002798). We used Chi-Square Test for comparison
of tumor frequencies in castrated mice and the Student’s T-
test, or One-Way ANOVA followed by Tukey’s tests for other
experiments. Values were considered statically significant for ∗p
< 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, and ∗∗∗∗p < 0.0001. Number
and types of replicates are indicated in each figure legend.
RESULTS
Sv2a Is Up Regulated in Gene Expression
Profiles From Murine and Human NEPC
Our initial aim was to identify molecules selectively expressed in
NEPC. Therefore, we interrogated gene expression profiles
that we have previously generated in the Transgenic
Adenocarcinoma of the Mouse Prostate model [TRAMP
(15)], comparing the transcriptome of adenocarcinoma and
NEPC occurring in TRAMP mice either spontaneously (18)
or following pharmacologic inhibition of MCs with cromolyn
(9) (all identified as “Mouse NEPC”). We also included the
analyses of published data by comparing the transcriptome of
TRAMP-derived prostate-cancer stem-like cells with NEPC
or adenocarcinoma features [(19); identified as “NEPC cell
lines”]. To increase translational relevance, results obtained from
murine models were compared with gene expression profiles
obtained from a publicly available data set comprising human
metastatic NEPC and CRPC [identified as “Human NEPC”;
(2)]. In search of possible commonly expressed drug targets, we
analyzed the lists of up-regulated genes (log2FC > 1 and adj.
p-value < 0.05; Figure 1A). The Metacore software was used to
identify drugs targeting the proteins encoded by the 20 genes
commonly up regulated in all the three data sets (Figures 1A,B).
We found that two of these genes, Sv2a and Birc5, encode for
proteins that are targeted by available drugs (Figure 1B). Birc5
is the gene encoding for Survivin, an antiapoptotic protein
overexpressed in several cancer types and already largely
investigated in clinical studies (22). Notably, in prostate cancer
an antisense oligonucleotide inhibitor of Survivin (23), as well as
immunotherapeutic approaches targeting this protein (24) are
currently tested.
Sv2a encodes for the synaptic vesicle protein SV2A, a
component of synaptic vesicles involved in cell exocytosis and
mainly expressed in neural and endocrine cells (25). SV2A is the
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FIGURE 2 | SV2A protein is expressed in murine NEPC and tumor-infiltrating MCs, in vivo. (A) Immunohistochemistry for SV2A (brown staining) on prostatic
intraepithelial neoplasia (PIN), adenocarcinoma or NEPC lesions from TRAMP mice. Arrows indicate positivity in infiltrating MCs (black arrows), monocytes (red arrows)
or scattered tumor cells (cyan arrows), respectively. Scale bars indicate magnifications. (B) Immunofluorescence for the MC-specific marker tryptase (TRYP; in green)
and SV2A (in red) in TRAMP prostate with adenocarcinoma. Blue staining is DAPI. In upper panels scale bars indicate magnification. Lower panels are further digital
magnifications of the original pictures.
target of the drug levetiracetam (26), which is commonly used in
epileptic patients, as it mitigates seizures (27).
To validate these results, we analyzed SV2A
expression in human prostate cancer tumor samples by
immunohistochemistry. According to in silico data, we found
a dim positivity for SV2A in prostate adenocarcinoma cells
and some positive infiltrating stroma cells (Figure 1C, upper
panels), whereas a strong and homogeneous expression of SV2A
characterized NEPC (Figure 1C, lower panels). This finding
prompted us to investigate whether SV2A could be a potential
therapeutic target in NEPC.
NEPC and MCs Robustly Express SV2A
To study the antitumor efficacy of levetiracetam, we moved
to the TRAMP mouse, a preclinical prostate cancer model in
which both adenocarcinoma and NEPC can occur (11, 28, 29).
We investigated SV2A expression at a protein level, performing
immunohistochemistry on prostate lesions from TRAMP mice.
SV2A was expressed in luminal cells in prostatic intraepithelial
neoplasia (PIN) whereas in adenocarcinoma lesions it was
negative in almost all tumor cells with few scattered tumor cells
showing mild positivity (Figure 2A upper and middle panels).
According to showed in silico and human data (Figure 1), SV2A
stained diffusely and was highly positive in all tumor cells in
NEPC lesions (Figure 2A, lower panels). Interestingly, in PIN
and adenocarcinoma lesions we found high expression of SV2A
by infiltrating stroma cells, particularly MCs and monocytes
(Figure 2A upper and middle panels). Indeed, we know from
our previous work (9) that MCs infiltrate prostate lesions and
that their number increases from PIN to adenocarcinoma,
whereas it is low in tumors with anaplastic/NEPC
features, in both TRAMP mice and patients. Besides
immunohistochemistry, we also confirmed the expression
of SV2A in MCs infiltrating TRAMP prostates by double
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FIGURE 3 | SV2A protein is expressed in murine NEPC cell lines and bone marrow derived MCs. (A) Immunohistochemistry for SV2A (brown staining) on cytospins of
T1525, T23, or ST4787 tumor cell lines or in vitro cultured- bone marrow derived MCs. Scale bars indicate magnifications. (B) Digital quantification for SV2A staining
intensity in (B), performed with Image J software. Dots indicate biological replicates. (C) Representative western blot for SV2A on T1525, T23, ST4787 tumor cell lines
and bone marrow derived MCs. Actin was used as loading control. The experiment was repeated four times. (D) Digital quantification of SV2A expression in (C),
normalized on actin, performed with Image J software. Dots indicate biological replicates. Anova followed by Tukey’s test: *p < 0.05, **p < 0.01, ***p < 0.001, and
****p < 0.0001.
immunofluorescence staining with the MC-specific marker
tryptase (Figure 2B).
We then tested SV2A expression by immunohistochemistry
on cytospins from a panel of TRAMP-derived prostate
cancer cell lines (T1525, T23, and ST4787) generated in
our laboratory [Ref (9) and Supplementary Figure 1], and
on in vitro-cultured bone marrow-derived MCs (BMMCs).
Results showed mild positivity in T1525 cells, representative of
well-differentiated, initial stage adenocarcinoma, whereas T23
cells, representative of poorly differentiated adenocarcinoma
post epithelial-mesenchymal transition (EMT) were negative
(Figures 3A,B). We can therefore suppose that T1525 cells
model those scattered adenocarcinoma cells that express mild
levels of SV2A in TRAMP tumors (Figure 2A cyan arrows),
whereas T23 cells are representative of the most abundant
SV2A negative adenocarcinoma cells. In line with expression
observed in vivo, both the NEPC cell line ST4787 and BMMCs
were strongly positive for SV2A (Figures 3A,B). We obtained
a similar pattern of SV2A expression by western blot analysis
on proteins extracts from tumor cell lines and BMMCs
(Figures 3C,D).
These results show that NEPC cells and MCs, both in vitro
and in vivo, express high levels of SV2A, therefore suggesting
that they could be both potentially affected by treatment
with levetiracetam.
Levetiracetam Slightly Reduces the
Proliferation of SV2A Expressing Tumor
Cells and Inhibits the Activation and
Degranulation of MCs in vitro
To verify the above hypothesis, we tested the activity of
levetiracetam on prostate cancer cell lines and BMMCs after
48 h of culture. Only high concentrations of levetiracetam (25
and 50mM) inhibited the proliferation of T1525 cells, which
express mild levels of SV2A, whereas it was inactive against
SV2A negative T23 cells at any of the doses tested (Figure 4A).
In the NEPC cell line ST4787, expressing high levels of SV2A
(Figure 3A), levetiracetam was moderately effective in reducing
cell proliferation even at a lower dose (10mM) (Figure 4A).
When tested on BMMCs, levetiracetam had no effect on cell
vitality (Figure 4A). AsMCs can release several solublemediators
by granule exocytosis in response to activation, we tested whether
levetiracetam hampered this function in BMMCs subjected to
different stimuli. Notably, this drug significantly inhibited the
release of beta-hexosaminidase in both IgE/Ag- and Ionomycin-
activated BMMCs, in a concentration dependent manner
(Figure 4B). Moreover, levetiracetam decreased the IgE/Ag
crosslink-mediated release of newly formed lipid mediators as
demonstrated by the reduced amounts of leukotrienes C4, D4,
and E4 measured in cell supernatants. Nevertheless, this effect
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FIGURE 4 | Levetiracetam reduces tumor cell proliferation and MCs degranulation. (A) T1525, T23, or ST4787 tumor cell lines or bone marrow derived MCs, cells
were cultured for 48 h in the presence of different concentrations of levetiracetam, as indicated, and tested for proliferation with the XTT assay (Applichem).
Histograms show a pool of two different experiments; dots indicate biological replicates. Anova followed by Tukey’s test *p < 0.05, **p < 0.01, ***p < 0.001, and ****p
< 0.0001. (B–D) Release of β-hexosaminidase (B), leukotrienes (C), and TNF-α, IL-6 and MMP9 (D) in bone marrow derived MCs either unstimulated (Ctr-) or
stimulated with IgE/Ag, Ionomycin (Iono) or LPS. Levetiracetam was added at different concentrations, as indicated. N = 3 per group, experiment was repeated three
times. Data were analyzed with paired two-way Anova *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.
was lower if compared to inhibition of degranulation, and
it was not dose-dependent (Figure 4C). To test the possible
effects of levetiracetam on modulating cytokine secretion,
BMMCs were activated through the engagement of the high-
affinity IgE receptor (by IgE/Ag stimulation) or of TLR4 (by
LPS stimulation), and cell supernatants were tested by ELISA
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assays (Figure 4D). Levetiracetam reduced the quantity of IL-
6 and TNF-α released by BMMCs induced by stimulation
with both IgE/Ag and LPS at a drug concentration of 10 and
25mM (Figure 4D). Interestingly, the treatment with 25mM
levetiracetam also inhibited the release of MMP9 by BMMCs in
response to both stimuli (Figure 4D).
Results so far indicate that levetiracetam can reduce, albeit
partially, the proliferation of SV2A expressing tumor cells, and
can prevent the degranulation of MCs after stimulation.
Levetiracetam Reduces Adenocarcinoma
and NEPC in vivo
Given the effect of levetiracetam in inhibiting the degranulation
of MCs, we investigated whether this drug could reduce
their adenocarcinoma promoting function in vivo. We know
from our previous work that MCs can sustain the growth
of early-stage, well-differentiated T1525 cells when injected
subcutaneously in syngeneic mice, through the provision of
soluble mediators including MMP9 (9). On the contrary, MCs
are dispensable for in vivo growth of poorly-differentiated,
EMT-like T23 adenocarcinoma cells, which can self-produce
MMP9 (30). We therefore compared tumor growth in mice
subcutaneously challenged with T1525 or T23 cells and
treated with the MC-stabilizer cromolyn or with levetiracetam.
According to our hypothesis, both drugs reduced the growth
of T1525-derived tumors (Figure 5A), but not of T23-derived
tumors (Figure 5B). As expected, in untreated mice bearing
T1525 tumors immunohistochemistry and immunofluorescence
showed strong MMP9 production by infiltrating MCs and not by
T1525 tumor cells (Figures 5C,D and Supplementary Figure 2),
whereas in T23 tumors MMP9 was mild and diffusely
expressed by tumor cells and no infiltrating MCs were detected
(Figures 5E,F). Notably, treatment with either cromolyn or
levetiracetam blunted MMP9 production by MCs in vivo
(Figures 5C,D and Supplementary Figure 2), but it did not
affect MMP9 expression in T23 tumor cells (Figure 5E). We can
conclude that the efficacy of levetiracetam in limiting the growth
of T1525-derived tumors is due, in part, to its effect in blocking
MCs degranulation and consequent adenocarcinoma-promoting
activity. On the contrary, levetiracetam is ineffective against T23-
derived tumors, which do not express SV2A and do not depend
on MCs support for their growth.
We finally tested the activity of levetiracetam against NEPC
tumor cells, in vivo. We found that levetiracetam, but not
cromolyn, partially reduced tumor growth in mice challenged
with the NEPC cell line ST4787 (Figure 5G). These results
indicate that, as expected from our previous data (9, 11),
inhibition of MCs is ineffective against NEPC. Nevertheless,
as NEPC cells express SV2A, they can be directly targeted
by levetiracetam.
To better mimic a clinical setting of NEPC occurring as
relapse following ADT, we tested the antitumor activity of
levetiracetam in TRAMP mice subjected to surgical castration.
Mice were castrated at 20 weeks of age and analyzed by
necropsy 10 weeks later. As from literature and our previous
results, we know that untreated TRAMP mice on a C57BL/6
background spontaneously develop prostate adenocarcinoma,
and de-novo NEPC arises in a small 10% fraction of mice (10,
28, 29). After castration, the frequency of NEPC (comprising
both de-novo and treatment-related NEPC), raised up to
58% of mice (11 out of 19 mice; Figure 6A). Histologically,
NEPC tumors were composed of sheets and nests of medium-
sized to large cells with high nuclear to cytoplasmic ratio
and/or anaplastic morphology (Figure 6B), expressing the NEPC
marker synaptophysin (SYP) and either negative (in case of
“pure” NEPC, as shown in Figure 6C) or positive for CK8 [in
case of NEPC tumors with mixed adenocarcinoma and NE
features, ref. (5), as shown in Supplementary Figure 1A]. The
remaining mice in the castrated cohort showed signs of high-
grade prostatic intraepithelial neoplasia with or without focal
carcinomatous transformation characterized by CK8 positive
atypical cells that formed distorted/ill-defined glands within the
stroma (HGPIN/ADENO, Figures 6B,C; found in 3 out of 19,
corresponding to 16% of mice; Figure 6A); or signs of glandular
involution/tumor regression (REG, Figures 6B,C; found in 5 out
of 19, corresponding to 26% of mice Figure 6A). Administration
of levetiracetam after castration resulted in a reduction of the
frequency of NEPC (found in 7 out of 19, corresponding to 37%
of mice, Figure 6A) and a marked increase of mice showing only
signs of regression (12 out of 19, corresponding to 63% of mice).
Notably, none of the TRAMP mice treated with levetiracetam
after castration developed lesions classified as HGPIN/ADENO
(Figure 6A).
Altogether these findings suggest that pharmacological
targeting of SV2A with the drug levetiracetam can reduce NEPC
development after androgen ablation/castration. Levetiracetam
can also partially inhibit the growth of prostate adenocarcinoma,
via MCs inactivation.
DISCUSSION
Treatment with ADT/ARPI in patients with CRPC ultimately
fails, due to mechanisms of resistance associated with cellular
plasticity and the emergence of treatment-related NEPC (4, 6),
and the diagnosis of patients with advanced prostate cancer
remains dismal. Therefore, the identification of novel therapeutic
targets for CRCP and NEPC is an urgent unmet clinical need.
Utilizing an in silico drug repurposing approach (14), we
found that human and murine NEPC overexpress SV2A, which
is the target of the antiepileptic drug levetiracetam. Protein-
target validation by immunohistochemistry led us discover by
serendipity that SV2A is expressed also by tumor-infiltrating
MCs. As we previously unraveled the dual role of MCs either
promoting or preventing prostate cancer according to its
adenocarcinoma or NE phenotype (9, 11), the identification of
SV2A as a common target on MCs and NEPC prompted us to
test whether levetiracetam could be effective on both prostate
cancer histotypes.
Levetiracetam has never been tested in prostate cancer cells
before our study, whereas it has already showed anti-proliferative
capacity against glioma cells in vitro (31). Albeit clinical testing of
levetiracetam in patients with glioblastoma did not associate with
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FIGURE 5 | Levetiracetam partially inhibits prostate adenocarcinoma and NEPC growth in mice with subcutaneous tumors. (A,B) Tumor growth in C57BL/6 mice
injected subcutaneously with T1525 (A) or T23 (B) cells and treated with cromolin (10 mg/Kg/Day; i.p., 5 days/week) or levetiracetam (60 mg/Kg/Day, daily in drinking
(Continued)
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FIGURE 5 | water), starting from day 4 after tumor challenge. N = 5 mice in each group. Experiment was repeated three times. Anova followed by Tukey’s test *p <
0.05. (C) Immunohistochemistry (brown staining) for MMP9 in T1525-derived tumors, collected from mice treated as in (A). Arrows indicate MCs infiltrating the
stroma. Scale bars indicate magnification. Histogram reports digital quantification of MMP9 staining intensity, performed with Image J software. Anova followed by
Tukey’s test *p < 0.05, **p < 0.01. (D) Immunofluorescence for MMP9 (in green) and the specific MC-marker tryptase (TRYP; in red) on T1525 tumors collected from
untreated mice or from mice treated with cromolyn or levetiracetam as in (A). Blue staining is DAPI. Images are digital magnifications of the original pictures (taken with
×630 magnification) shown in Supplementary Figure 2. (E) Immunohistochemistry for MMP9 in T23-derived tumors, collected from mice treated as in (B). Scale
bars indicate magnification. Histogram reports digital quantification of MMP9 staining intensity, performed with Image J software. (F) Immunofluorescence for MMP9
(in green) and the specific MC-marker tryptase (TRYP; in red) on T23 tumors collected from untreated mice. Blue staining is DAPI. Scale bars indicate magnification.
(G). Tumor growth in C57BL/6 mice injected subcutaneously with ST4787 cells and treated with cromolyn (10 mg/Kg/Day; i.p., 5 days/week) or levetiracetam (60
mg/Kg/Day, daily in drinking water), starting from day 4 after tumor challenge. N = 5 mice in each group. Experiment was repeated three times. Anova followed by
Tukey’s test *p < 0.05.
improved progression-free survival and/or overall survival (32),
a case report documented regression of lung metastatic lesions
in a man with adenoid cystic carcinoma, in which levetiracetam
was administered with the sole intent to relief epilepsy, and
after the failure of several lines of therapy against the tumor
(33). Here, we show that levetiracetam has some efficacy against
both adenocarcinoma and NEPC, in vivo, in subcutaneous and
spontaneous murine models. Nevertheless, the extent of tumor
inhibition that we observed in this study is limited, but suggestive
for further evaluation of levetiracetam in combination with other
therapeutic approaches in prostate cancer.
In vivo the MC-stabilizer cromolyn and levetiracetam have
comparable effect in restraining T1525-prostate cancer tumors,
which strictly depend on MCs provision of MMP9 for their
growth (9). Therefore, we can conclude that the activity in
blocking prostate adenocarcinoma is due to the solely targeting
of MCs degranulation, and exclude an additional effect of
levetiracetam on adenocarcinoma cells. Indeed, albeit T1525 cells
express intermediate levels of SV2A, their proliferation in vitro
can be limited only by a very high concentration of levetiracetam,
which is far higher than that of 60 mg/Kg day, used in our in vivo
experiments and corresponding to the maximum recommended
for patients (16, 17). Studies in mouse or rat models have used
higher concentrations of levetiracetam up to 600 mg/Kg day
without showing any additional side effect (34, 35), therefore
suggesting the possibility of testing high-doses of levetiracetam in
vivo in prostate cancer models, with the aim to target both MCs
and those scattered adenocarcinoma cells expressing mild levels
of SV2A.
On the contrary, the inhibitory effect of levetiracetam on
NEPC is rather quite specific and depends on strong expression
of SV2A in NE tumor cells. Interfering with the mechanism of
cell exocytosis could indeed block the release of autocrine or
paracrine factors involved in cell proliferation. According to this
hypothesis, it has been shown that the botulinum toxin type A
(BTA), which molecularly binds to SV2A (36), can inhibit the
growth of SV2A-expressing LNCaP prostate cancer cells, both in
vitro and in vivo (37).
Given the above considerations, the therapeutic efficacy of
levetiracetam that we observed against both adenocarcinoma
and NEPC in castrated TRAMP mice, likely results
from both the inhibition of adenocarcinoma promoting-
functions of MCs and from the direct action on NE tumor
cells, respectively.
Additional potential antitumor activity of levetiracetam could
come from the known activity as histone deacetylase (HDAC)
inhibitors of several antiepileptic drugs including levetiracetam
or valproic acid (38). Interestingly, a study analyzing the effect
of long-term antiepileptic treatment on PSA levels in tumor-
free patients, albeit limited to a low number of subjects, showed
that treatment with either valproic acid or levetiracetam was
associated to lower levels of circulating PSA (39).
Nonetheless, our evidence that levetiracetam does not
restrain, both in vitro and in vivo, the growth of SV2A-
negative T23 tumor cells, likely excludes the relevance of HDAC-
inhibition properties of this drug in our setting. These data are
in line with the disappointing results of clinical trials testing a
variety of HDAC inhibitors in prostate cancer patients (40).
To our knowledge, besides being the first description of the
use of levetiracetam against prostate cancer, it is also the first
time that levetiracetam is used to inhibit the degranulation
of MCs. MCs are involved in the pathogenesis of various
human disorders, such as mastocytosis, urticaria, allergic rhinitis,
asthma, tumors, and autoimmune diseases (41) and several MC-
modulating drugs have been largely investigated in the past
decades (42). These substances include molecules that reduce
the number of MCs and/or inhibit the MC activation process
such as omalizumab, cromolyn, and imatinib; or molecules that
interfere with the process of release of mediators, including
steroids and non-steroidal anti-inflammatory drugs. A variety
of these MC-modulating drugs are already approved by the
Food and Drug Administration Agency, especially for the
treatment of hypersensitivity diseases (43). However, there are
no pharmacologic agents that can exclusively and selectively
suppress MC activation.
We have herein observed an inhibitory effect of levetiracetam
on the release of preformed mediators as well as newly
synthesized molecules from MCs that had been previously
activated through different pathways. The mechanism of
action of levetiracetam is not exactly clear, but it is known
that this antiepileptic drug interferes with the process of
exocytosis of neurotransmitters and that this exocytosis is
down-regulated via reduced calcium inward currents (44).
Cataldi et al. (45) demonstrated that levetiracetam inhibits
calcium release from intracellular inositol-trisphosphate (IP3)-
sensitive granules in PC12 cells. IP3-dependent release of
calcium from intracellular stores is regarded as a major
factor responsible for the consistent elevation of Ca2+ ions
Frontiers in Immunology | www.frontiersin.org 11 March 2021 | Volume 12 | Article 622001
Sulsenti et al. Levetiracetam Repurposing in Prostate Cancer
FIGURE 6 | Levetiracetam inhibits adenocarcinoma and NEPC growth in castrated TRAMP mice. (A) TRAMP mice were castrated at 20 weeks of age and left
untreated (n = 19) or treated daily with levetiracetam (60 mg/Kg/Day in drinking water; n = 19), starting one-week post castration. All mice were killed at 30 weeks of
(Continued)
Frontiers in Immunology | www.frontiersin.org 12 March 2021 | Volume 12 | Article 622001
Sulsenti et al. Levetiracetam Repurposing in Prostate Cancer
FIGURE 6 | age and prostates collected for histopathology. Graph depicts the relative percentage of lesions scored as tumor involution/regression (REG), high-grade
intraepithelial neoplasia with or without focal adenocarcinoma (HGPIN/ADENO) or neuroendocrine tumor (NEPC). Please refer to materials and methods for detailed
criteria utilized for tumor lesion classification. Chi Square Test: ****p < 0.0001. Numbers within bar represent the relative percentage of mice presenting each type of
lesion. (B,C) Representative images of prostates of castrated TRAMP mice showing evidence of REG, HGPIN/ADENO, or NEPC. Images show hematoxylin and eosin
staining (B); or immunofluorescence (C) staining for CK8 (green), SYP (red), and DAPI (blue). Scale bars indicate magnification.
observed in epileptic neurons (46). Indeed, both the exocytosis
of pre-stored granules and the release of cytokines by
MCs depend on calcium signaling (47). Consequently, the
impaired calcium mobilization induced by levetiracetam could
decrease the magnitude of the degranulation response of
MCs to different activating stimuli. This could explain the
reduced amounts of released mediators that we detected in
response to different activating stimuli (IgE/Ag, Ionomycin,
and LPS). However, further studies on the mechanism of
action of levetiracetam in MCs are required to better explain
the reduced secretion of mediators that we observed in
this study.
In conclusion, we here demonstrate that levetiracetam could
be efficaciously repurposed to defeat NEPC and to target MCs
activation in the context of their supportive function for prostate
adenocarcinoma. Our data pave the way to further investigation
on the use of levetiracetam in cancer therapy, also in combination
with other agents, and in other pathological contexts associated
with MCs hyperactivity such as hypersensitivity, mastocytosis, or
autoimmune disorders.
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